The CMS released a proposed rule that would require drugmakers to list prices for their drugs in their consumer advertising.
Five doctors, a pharmacist and three medical assistants were among 10 defendants charged with taking in more than $5 million by illegally prescribing millions of oxycodone pills to patients, including apparent drug addicts, who had no legitimate medical need for them.
Sixteen months after Walgreens Boots Alliance concluded a disastrous relationship with Theranos, the now-defunct Silicon Valley blood-testing company, the pharmacy giant has linked up with LabCorp, one of the world's largest clinical laboratory operators.
U.S. regulators Friday expanded the use of Merck's cervical cancer vaccine to adults up to age 45.
Wholesale drug distributor AmerisourceBergen agreed to pay federal and state governments $625 million for illegally distributing misbranded drugs, including pre-filled cancer syringes.
Gilead Sciences' move to launch generic versions of two hepatitis C treatments could motivate states to eliminate restrictions on their Medicaid and inmate populations.
An analysis of brand-name prescription drug prices shows it's been business as usual for drugmakers, with far more price hikes than cuts. The number of increases slowed somewhat and were not quite as steep as in past years.
Gilead will start selling the generics for chronic hepatitis C in January at a $24,000 list price, a significant discount compared to the price for its branded alternatives, which can cost nearly $100,000 for a full course of treatment.
Instagram has begun using some drug-related hashtags, such as “opioid” and “uppers,” to steer users of the app to information about opioid treatment and recovery.
Hospitals and pharmacies are challenged to play a pivotal role in the nation's drug supply chain: dispensing medications to the public. Among the many regulations—state and federal—that govern the activities of dispensing medicine, are 3 critical laws pertaining to the safety and...
A push by Big Pharma to claw back Medicare Part D donut hole money as part of the opioids package has hit sharp Democratic opposition.
California's insurance commissioner accused pharmaceutical giant AbbVie of illegally plying doctors with cash, gifts and services to prescribe Humira, tainting their relationship with patients and driving up insurance costs.